Business Wire

Sandvine Appoints Chief Ethics & Compliance Officer and Board Advisor as Part of Strengthened Commitment to Internet Freedom and Digital Rights

Share

Carol Tate will serve as CCO following her tenure as Chief Compliance Officer at IntelFormer President & CEO of Human Rights First, Michael Breen, appointed as Advisor to the Board of Directors

Today, Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, announced the appointments of Carol Tate as Chief Ethics & Compliance Officer, effective February 3, and Michael Breen as Advisor to the Board of Directors, effective January 1. Working closely with teams across the Company and in collaboration with its Board of Directors, Tate will spearhead compliance and due diligence initiatives to help facilitate Sandvine’s transition into a technology solution leader for democracies. Working directly with the Company’s Board of Directors, Breen is advising on human rights matters, including its engagement with non-governmental organizations to inform the Company’s human rights due diligence.

With decades of legal, risk, and compliance experience in the public and private sectors, Tate brings extensive experience embedding ethics and compliance into technological deployment and innovation on a global scale. She most recently served as Vice President and Chief Compliance Officer at Intel Corporation (NASDAQ: INTC) (“Intel”), where she led the organization’s global ethics and compliance function, which included driving initiatives to promote the company’s values and ethical culture, encourage open reporting, and reinforce Intel’s commitment to product responsibility in connection with Intel’s technology.

Prior to Intel, Tate held senior leadership roles within the ethics and compliance functions at McCarthy Holdings, Inc., Flextronics International Ltd., and Motorola. She also served as a senior attorney with the U.S. Securities and Exchange Commission’s Enforcement Division.

“As we operate in an increasingly complex digital environment, Sandvine’s focus on driving technological innovation while promoting internet freedom and digital rights could not be more critical,” said Tate. “I am excited to join a team and organization focused on providing high-quality products and premier customer service while facing these challenges head-on through close and productive partnerships with all stakeholders.”

Breen, an executive leader, strategist, policy expert and former military officer, has diverse experience leading complex organizations at the intersection of technology, global security, human rights, politics, and markets. He previously served as President & CEO of Human Rights First, a US-based organization confronting global human rights abuse, authoritarianism, and extremism through technology innovation and deployment, crisis response, policy development and advocacy, research, and legal services. Prior to leading Human Rights First, Breen acted as President & CEO of the Center for National Policy and the Truman National Security Project, served in the Obama administration’s Office of White House Counsel, and co-founded the International Refugee Assistance Project. He began his career as a decorated US Army officer, leading soldiers in combat in Iraq and Afghanistan.

“At a critical inflection point, Sandvine worked diligently to rechart its course, commit to being a positive and material contributor to the protection of human rights around the world, and double down on its mission to help people work, learn, entertain, and communicate. That resilience speaks to the Company’s potential to build itself into a values-driven technology solutions market leader,” said Breen. “I look forward to working closely with the Sandvine Board of Directors and the Company’s executive leadership team to help Sandvine navigate the challenges of today’s digital landscape.”

“Sandvine’s appointments of Carol and Michael are a direct reflection of the Company’s strengthened commitment to internet freedom and both digital and human rights, and we are honored to welcome them aboard,” added Carney Hawks, Chairman of the Board of Sandvine. “Carol’s extensive and successful track record collaborating with government and regulatory stakeholders, customers, trade groups, NGOs, and colleagues to deliver technological excellence governed by the highest ethical standards, combined with Michael’s exceptional background leading organizations dedicated to mitigating the world’s most complex issues across technology, human rights, global security and political dimensions, will be immensely valuable to Sandvine in this new chapter.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115186859/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye